Vaxcyte Inc
PCVX
Market Cap$3.95B
Close$
$2.60
91.7% downside
Current Fair Value
91.7% downsideOvervalued by 91.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.95 Billion |
|---|---|
| Enterprise Value | $3.63 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.8 |
| Beta | 1.26 |
| Outstanding Shares | 122,845,174 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -8.12 |
|---|---|
| PEG | -71.9 |
| Price to Sales | - |
| Price to Book Ratio | 1.2 |
| Enterprise Value to Revenue | 251.27 |
| Enterprise Value to EBIT | -6.83 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Vaxcyte Inc
14,000 employees
CEO: Grant Pickering Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-fre...